Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.

[1]  A. Wolff,et al.  Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Lippert,et al.  Influence of hospital volume on the frequency of abdominoperineal resection and long-term oncological outcomes in low rectal cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  C. Tournigand,et al.  Adjuvant therapy for stage II and III colorectal cancer. , 2007, Seminars in oncology.

[4]  N. Wolmark,et al.  Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. , 2006, Journal of the National Cancer Institute.

[5]  A. Benson.  New approaches to the adjuvant therapy of colon cancer. , 2006, The oncologist.

[6]  A. Neugut,et al.  Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Kornmann,et al.  Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment: Results of a Randomized Trial Comparing Modulation of 5-FU + Levamisole With Folinic Acid or With Interferon-α , 2005, Annals of surgery.

[8]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[9]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[11]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. El‐Serag,et al.  Surgical Volume and Long-Term Survival Following Surgery for Colorectal Cancer in the Veterans Affairs Health-Care System , 2004, American Journal of Gastroenterology.

[13]  J. Meyerhardt,et al.  Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence , 2003, Annals of Internal Medicine.

[14]  J. Meyerhardt,et al.  Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma , 2003, Cancer.

[15]  A. Stewart,et al.  A New TNM Staging Strategy for Node-Positive (Stage III) Colon Cancer: An Analysis of 50,042 Patients , 2002, Annals of surgery.

[16]  F. Mosca,et al.  Prognostic Evaluation of Stage B Colon Cancer Patients is Improved by an Adequate Lymphadenectomy: Results of a Secondary Analysis of a Large Scale Adjuvant Trial , 2002, Annals of surgery.

[17]  H. Beger,et al.  Toxicity and effects of adjuvant therapy in colon cancer: results of the german prospective, controlled randomized multicenter trial fogt-1 , 2001, Journal of Gastrointestinal Surgery.

[18]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[19]  G. Wagner.  The Classification of Malignant Tumors , 1987, Methods of Information in Medicine.

[20]  P. Loehrer.  Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging , 2006 .

[21]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.